GlassScriptPhysician profile
Gordon Kim Rainey
NPI 1528046331
$13,816.95
in general payments reported to CMS, 2019-2025
36 companies · $2,623 in 2025
The $2,623 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $177 · 2021: $1,295 · 2022: $1,615 · 2023: $4,773 · 2024: $2,076 · 2025: $2,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,007 · Consulting Fee: $2,000 · Education: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,006.84 |
| Consulting Fee | $2,000.00 |
| Education | $465.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $2,545.07 | 2022-2024 | Vtama |
| Abbvie INC. | $1,978.97 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,333.65 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Janssen Biotech, INC. | $727.88 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $644.68 | 2019-2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $617.42 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $586.79 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $516.61 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $429.82 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $426.60 | 2019-2025 | Jublia |
| Leo Pharma INC. | $425.75 | 2021-2025 | Adbry, Anzupgo |
| Revance Therapeutics, INC. | $324.24 | 2024-2025 | Daxxify |
| Vyne Pharmaceuticals INC. | $318.85 | 2020-2021 | |
| Lilly USA, LLC | $300.12 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $295.39 | 2021-2025 | Odomzo, Blu-U, Ilumya |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $262.93 | 2021-2025 | Opzelura |
| Almirall LLC | $242.69 | 2019-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $235.59 | 2023-2025 | Zoryve |
| Organon LLC | $233.82 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $211.24 | 2023-2024 | Ycanth |
| Amgen INC. | $165.46 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $129.23 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Dusa Pharmaceuticals, INC. | $123.26 | 2019 | |
| Journey Medical Corporation | $121.19 | 2022-2023 | |
| Pfizer INC. | $106.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.46 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $76.72 | 2022-2023 | Xolair |
| Medimetriks Pharmaceuticals, INC. | $69.06 | 2022-2025 | Clindacin Etz |
| Epi Health, LLC | $29.03 | 2022 | |
| Tactile Systems Technology INC | $28.11 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Organogenesis INC. | $20.64 | 2024 | |
| Fresenius Kabi USA, LLC | $16.71 | 2023 | Idacio |
| Botanix Sb INC | $16.63 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $16.01 | 2022 | |
| Kyowa Kirin, INC. | $15.47 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Rainey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.